



Company Announcement

Avexa to manufacture ATC capsules for clinical use

Melbourne, Australia, Thursday December 12, 2013: Australian biotechnology company Avexa Limited [ASX:AVX] today announced that it will convert part of its existing stockpile of apricitabine (ATC) – its late stage drug candidate for drug-resistant-HIV – into capsules for clinical use.

Avexa has engaged NextPharma – a global pharmaceutical contract development and manufacturing organisation headquartered in the United Kingdom – to manufacture the ATC capsules, which have a shelf life of three years. Avexa is working with its commercial partner Link Healthcare to most effectively meet the demand for requests for ATC treatment.

“Avexa is fortunate in having substantial stocks of ATC,” said Mr Iain Kirkwood, Chairman of Avexa. “We are delighted to work with NextPharma to make available supplies of the finished product. Together with our marketing partner, Link Healthcare, we look forward to seeing ATC make a difference to the lives of people who need it.”

ATC is expected to be available through Link Healthcare in the second half of 2014.

About Avexa Limited

Avexa Limited is a Melbourne-based biotechnology company with a focus on discovery, development and commercialization of small molecules for the treatment of infectious diseases. Avexa’s key projects include apricitabine (ATC) for the treatment of drug resistant HIV, an HIV integrase program and an antibiotic program for antibiotic-resistant bacterial infections.

About NextPharma

NextPharma provides a full range of pharmaceutical services across the entire supply chain, including pharmaceutical development, clinical trials services, analytical services, commercial manufacturing and packaging, generic dossiers and licensing.

About Link Healthcare

Link Healthcare is a privately owned specialist Pharmaceutical and Medical Technology business. Link’s mission is to strive for excellence in the marketing of a vitally important and unique range of specialist therapeutic products. Link provides exceptional sales and marketing infrastructure and is partnered with blue chip pharmaceutical companies from around the world. This allows the group to offer a unique and substantial portfolio of 'medicine that matters.'

For more information:

Mr Iain Kirkwood
Avexa Chairman
Ph: +61 408 473 496

Dr Jonathan Coates
Avexa CSO and Interim CEO
Ph: +61 3 8888 1040

Richard Allen
Oxygen Financial PR
Ph: + 61 3 9915 6341